The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Anticipated Rise In Market Value Of The Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market During The Forecast Period?
The market for messenger ribo nucleic acid (mrna) vaccine contract development and manufacturing organizations (cdmo) has experienced significant expansion recently. This market is projected to expand from $8.41 billion in 2025 to reach $9.68 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 15.1%. Historically, this expansion was driven by several factors, including covid 19 vaccine programs, a surge in biotech startups, insufficient in-house manufacturing capabilities, an uptick in contract manufacturing, and accelerated mrna platform validation.
The messenger ribo nucleic acid (mrna) vaccine contract development and manufacturing organization (cdmo) market size is anticipated to expand rapidly in the upcoming years. It is projected to achieve $17.1 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 15.3%. This growth during the forecast period can be attributed to the increasing use of mRNA cancer vaccines, the emergence of personalized vaccines, a rise in CDMO partnerships, the demand for quick scale manufacturing, and an expanding pipeline of mRNA therapies. Significant trends for the forecast period include lipid nanoparticle formulation services, expedited mRNA process scale-up, integrated fill-finish outsourcing, flexible modular vaccine manufacturing suites, and comprehensive end-to-end mRNA development services.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=33214&type=smp
Which Drivers Are Supporting The Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market Growth?
The increasing occurrence of infectious and newly developing diseases is projected to drive the expansion of the mRNA vaccine CDMO market in the future. These diseases are defined as ailments stemming from pathogenic microbes that disseminate quickly or appear afresh, influenced by elements like environmental shifts, increasing urbanization, and greater worldwide connections. Enhanced international travel, higher population concentrations, and intertwined supply networks have accelerated the spread of pathogens, leading to more frequent, extensive, and challenging-to-contain disease outbreaks. mRNA vaccine CDMOs are vital in confronting these issues by facilitating the swift development, mass-producible manufacturing, and adaptable production of vaccines essential for countering evolving infectious dangers. The specialized manufacturing infrastructure and technical know-how required by mRNA technologies lead vaccine developers to partner with contract development and manufacturing organizations to speed up project timelines and guarantee production capability during epidemics. As an example, in May 2024, the World Health Organization (WHO), a specialized global health agency of the United Nations based in Switzerland, reported that by 30 April 2024, over 7.6 million dengue cases were registered worldwide with WHO, comprising 3.4 million confirmed cases, upwards of 16,000 severe cases, and exceeding 3,000 fatalities. This surge was notably prominent in the Region of the Americas, where the count of cases surpassed seven million by April 2024, which was higher than the 2023 annual total of 4.6 million cases. Consequently, the increasing incidence of infectious and emerging diseases is fueling the expansion of the mRNA vaccine CDMO market.
Which Segment Classifications Are Used In The Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market Segment Analysis?
The messenger ribo nucleic acid (mrna) vaccine contract development and manufacturing organization (cdmo) market covered in this report is segmented –
1) By Service Type: Process Development; Manufacturing; Analytical And Quality Control; Fill Finish; Packaging; Other Service Types
2) By Vaccine Type: COVID-19 Vaccines; Cancer Vaccines; Infectious Disease Vaccines; Other Vaccine Types
3) By Scale of Operation: Preclinical; Clinical; Commercial
4) By End-User: Pharmaceutical Companies; Biotechnology Companies; Research Institutes; Other End-Users
Subsegments:
1) By Process Development: Formulation Optimization; Cell Line Development; Upstream Process Development; Process Scale-Up
2) By Manufacturing: Lipid Nanoparticle Production; Enzymatic Capping; Purification Process
3) By Analytical And Quality Control: Potency Testing; Purity Analysis; Stability Testing; Identity Testing; Microbial Testing
4) By Fill Finish: Aseptic Filling; Vial Filling; Syringe Filling; Lyophilization
5) By Packaging: Primary Packaging; Secondary Packaging; Labeling Operations; Cold Chain Packaging; Unit Dose Packaging
6) By Other Service Types: Regulatory Support Services; Technology Transfer Services; Contract Development Services; Consulting Services; Supply Chain Management
Which Trends Are Expected To Impact The Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market?
Major companies operating in the mRNA vaccine CDMO market are increasingly focusing on advanced innovations like phase-appropriate GMP mRNA contract development and manufacturing services to accelerate preclinical and IND-enabling development, all while maintaining regulatory-aligned quality standards and shorter timelines. Phase-appropriate GMP-like mRNA manufacturing refers to a production approach designed to deliver high-quality, regulatory-aware mRNA material suitable for preclinical and early development stages, without the cost and operational complexity associated with full GMP manufacturing. For instance, in May 2025, GenScript Biotech Corporation, a China-based global biotechnology reagents and services provider, launched a GMP-like mRNA manufacturing service aimed at supporting preclinical and IND-enabling development. The service delivers high-quality, regulatory-aware mRNA with reduced lead times and lower costs compared to traditional full GMP manufacturing, reflecting the growing demand for flexible, phase-appropriate CDMO solutions in the mRNA vaccine market.
Which Firms Are Contributing To The Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market Ecosystem?
Major companies operating in the messenger ribo nucleic acid (mrna) vaccine contract development and manufacturing organization (cdmo) market are Sanofi S.A., Thermo Fisher Scientific Inc., FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Danaher Corporation, Boehringer Ingelheim BioXcellence GmbH & Co. KG, AGC Biologics A/S, Eurofins Scientific SE, Lonza Group AG, BioNTech SE, Samsung Biologics Co. Ltd., WuXi Biologics (Cayman) Inc., Siegfried Holding AG, Recipharm AB, Vetter Pharma International GmbH, CordenPharma GmbH & Co. KG, Ajinomoto Bio-Pharma Services Inc., Novasep Holding S.A.S., Rentschler Biopharma SE, IDT Biologika GmbH, Wacker Biotech GmbH
Get The Full Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market Report:
Which Region Is The Largest In The Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market?
North America was the largest region in the mRNA vaccine contract development and manufacturing organization (CDMO) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the messenger ribo nucleic acid (mrna) vaccine contract development and manufacturing organization (cdmo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/customise?id=33214&type=smp
Browse Through More Reports Similar to the Global Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market 2026, By The Business Research Company
Vaccine Contract Manufacturing Market Report 2026
Mrna Cancer Vaccines And Therapeutics Market Report 2026
Therapeutic Bcg Vaccines Market Report 2026
https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model